December 3, 2018
Eli Lilly Japan rolled out its breast cancer treatment Verzenio (abemaciclib) on November 30, setting up a showdown with Pfizer’s Ibrance (palbociclib), the first drug in the CDK4/6 inhibitor class launched almost a year ago. Being second-in-class, Verzenio is now...read more